MedPath

Beijing haidian hospital

🇨🇳China
Ownership
-
Established
1949-01-01
Employees
-
Market Cap
-
Website
http://www.hdhospital.com/

Clinical Trials

6

Active:0
Completed:1

Trial Phases

3 Phases

Phase 2:2
Phase 4:1
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (50.0%)
Not Applicable
1 (25.0%)
Phase 4
1 (25.0%)

Exploratory Study of the Microbiome of Upper Gastrointestinal in the Pathogenesis of Multiple Primary Lung Cancer

Completed
Conditions
Multiple Primary Lung Cancer
Microbial Colonization
First Posted Date
2025-05-15
Last Posted Date
2025-05-15
Lead Sponsor
Beijing Haidian Hospital
Target Recruit Count
20
Registration Number
NCT06973499
Locations
🇨🇳

Beijing Haidian Hospital, Beijing, China

Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer

Phase 2
Recruiting
Conditions
Limited Stage Small Cell Lung Cancer
Interventions
First Posted Date
2021-09-05
Last Posted Date
2021-09-05
Lead Sponsor
Beijing Haidian Hospital
Target Recruit Count
20
Registration Number
NCT05034133
Locations
🇨🇳

Beijing Haidian Hospital, Beijing, China

Diagnostic Value of CircRNA-Uck2 for Acute Myocardial Infarction

Not Applicable
Conditions
Cardiac Disease
Acute Myocardial Infarction
Diagnoses Disease
First Posted Date
2017-05-31
Last Posted Date
2017-05-31
Lead Sponsor
Beijing Haidian Hospital
Target Recruit Count
178
Registration Number
NCT03170830
Locations
🇨🇳

Beijing Haidian Hospital, Haidian Section of Peking University Third Hospital, Beijing, China/Beijing, China

Clinical Characteristics and Microbiology of Community-Acquired Pneumonia

Conditions
Community-acquired Pneumonia
First Posted Date
2017-04-04
Last Posted Date
2017-04-05
Lead Sponsor
Beijing Haidian Hospital
Target Recruit Count
2000
Registration Number
NCT03098914
Locations
🇨🇳

Beijing Haidian Hospital, Beijing, Beijing, China

The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation

Phase 2
Conditions
Non-small Cell Lung Cancer(NSCLC)
Interventions
First Posted Date
2016-06-30
Last Posted Date
2016-06-30
Lead Sponsor
Beijing Haidian Hospital
Target Recruit Count
67
Registration Number
NCT02820116
Locations
🇨🇳

Beijing Haidian Hospital, Beijing, Beijing, China

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.